{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:16:58Z","timestamp":1787912218440,"version":"build-2784847793"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00203-026-04980-w","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:17:06Z","timestamp":1781255826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges"],"prefix":"10.1007","volume":"208","author":[{"given":"Sushama","family":"Agarwalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"4980_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/11786302251357775","volume":"19","author":"TA Abate","year":"2025","unstructured":"Abate TA, Birhanu AG (2025) Antibiotic use in livestock and environmental antibiotic resistance: a narrative review. Environ Health Insights 19:11786302251357775. https:\/\/doi.org\/10.1177\/11786302251357775","journal-title":"Environ Health Insights"},{"key":"4980_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.635597","volume":"11","author":"IM Abd-Allah","year":"2021","unstructured":"Abd-Allah IM, El-Housseiny GS, Yahia IS, Aboshanab KM, Hassouna NA (2021) Rekindling of a masterful precedent; bacteriophage: reappraisal and future pursuits. Front Cell Infect Microbiol 11:635597. https:\/\/doi.org\/10.3389\/fcimb.2021.635597","journal-title":"Front Cell Infect Microbiol"},{"key":"4980_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/antibiotics12020245","volume":"12","author":"ST Abedon","year":"2023","unstructured":"Abedon ST (2023) Ecology and evolutionary biology of hindering phage therapy: the phage tolerance vs. phage resistance of bacterial biofilms. Antibiotics 12:245. https:\/\/doi.org\/10.3390\/antibiotics12020245","journal-title":"Antibiotics"},{"key":"4980_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/138920110790725410","volume":"11","author":"ST Abedon","year":"2010","unstructured":"Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharma Biotechno 11:28\u201347. https:\/\/doi.org\/10.2174\/138920110790725410","journal-title":"Curr Pharma Biotechno"},{"key":"4980_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-60327-164-6_17","volume":"501","author":"ST Abedon","year":"2009","unstructured":"Abedon ST, Yin J (2009) Bacteriophage plaques: theory and analysis. Methods Mol Biol 501:161\u2013174. https:\/\/doi.org\/10.1007\/978-1-60327-164-6_17","journal-title":"Methods Mol Biol"},{"key":"4980_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/bact.1.2.15845","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1:66\u201385. https:\/\/doi.org\/10.4161\/bact.1.2.15845","journal-title":"Bacteriophage"},{"key":"4980_CR7","doi-asserted-by":"crossref","unstructured":"Abedon ST, Garc\u00eda P, Mullany P, Aminov R (2017) Phage therapy: past, present and future. Front Media SA 981","DOI":"10.3389\/978-2-88945-251-4"},{"key":"4980_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-025-00287-4","volume":"17","author":"IC Abraham","year":"2025","unstructured":"Abraham IC et al (2025) Examining the efficacy and safety of bacteriophage therapy on ESKAPE pathogens and its potential for mitigating disease outbreaks. Curr Treat Options Infect Dis 17:10. https:\/\/doi.org\/10.1007\/s40506-025-00287-4","journal-title":"Curr Treat Options Infect Dis"},{"key":"4980_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100784","volume":"18","author":"SLO Alenzi","year":"2026","unstructured":"Alenzi SLO et al (2026) The global epidemiology of antimicrobial resistance: trends, determinants, and public health implications. Cureus 18:e100784. https:\/\/doi.org\/10.7759\/cureus.100784","journal-title":"Cureus"},{"key":"4980_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30153132","volume":"30","author":"O Alessa","year":"2025","unstructured":"Alessa O et al (2025) Synthetic and functional engineering of bacteriophages: approaches for tailored bactericidal, diagnostic, and delivery platforms. Molecules 30:3132. https:\/\/doi.org\/10.3390\/molecules30153132","journal-title":"Molecules"},{"key":"4980_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106199","volume":"181","author":"Y Ali","year":"2023","unstructured":"Ali Y, Inusa I, Sanghvi G, Mandaliya VB, Bishoyi AK (2023) The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microb Pathog 181:106199. https:\/\/doi.org\/10.1016\/j.micpath.2023.106199","journal-title":"Microb Pathog"},{"key":"4980_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12866-025-03785-z","volume":"25","author":"Z Ali","year":"2025","unstructured":"Ali Z, Abdelkader K, Abdel-Fattah MM, Azmy AF, El-Gendy AO, Dishisha T (2025) Therapeutic potential of a newly isolated bacteriophage against multi-drug resistant Enterococcus faecalis infections: in vitro and in vivo characterization. BMC Microbiol 25:80. https:\/\/doi.org\/10.1186\/s12866-025-03785-z","journal-title":"BMC Microbiol"},{"key":"4980_CR13","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.22207\/JPAM.16.4.01","volume":"16","author":"FA Alqahtani","year":"2022","unstructured":"Alqahtani FA, Almustafa HI, Alshehri RS, Alanazi SO, Khalifa AY (2022) Combating antibiotic resistance in bacteria: the development of novel therapeutic strategies. J Pure Appl Microbiol 16:2201\u20132224. https:\/\/doi.org\/10.22207\/JPAM.16.4.01","journal-title":"J Pure Appl Microbiol"},{"key":"4980_CR14","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1093\/cid\/ciad483","volume":"77","author":"G Andrzej","year":"2023","unstructured":"Andrzej G, Mi\u0119dzybrodzki R, Jo\u0144czyk-Matysiak E, Kniotek M, Letkiewicz S (2023) Therapeutic phages as modulators of the immune response: practical implications. Clin Infect Dis 77:S433\u2013S439. https:\/\/doi.org\/10.1093\/cid\/ciad483","journal-title":"Clin Infect Dis"},{"key":"4980_CR15","unstructured":"Antimicrobial Resistance Division (AMR) S Prevention and Control (SPC) Global antibiotic resistance surveillance report 2025. In, p 114"},{"key":"4980_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094577","volume":"23","author":"C Aranaga","year":"2022","unstructured":"Aranaga C, Pantoja LD, Mart\u00ednez EA, Falco A (2022) Phage therapy in the era of multidrug resistance in bacteria: A systematic review. Int J Mol Sci 23:4577. https:\/\/doi.org\/10.3390\/ijms23094577","journal-title":"Int J Mol Sci"},{"key":"4980_CR17","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam S et al (2019) Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 19:2631\u20132639. https:\/\/doi.org\/10.1111\/ajt.15503","journal-title":"Am J Transplant"},{"key":"4980_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389","volume":"7","author":"S Aslam","year":"2020","unstructured":"Aslam S et al (2020) Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis 7:ofaa389. https:\/\/doi.org\/10.1093\/ofid\/ofaa389","journal-title":"Open Forum Infect Dis"},{"key":"4980_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2004356","volume":"16","author":"C Barbosa","year":"2018","unstructured":"Barbosa C, Beardmore R, Schulenburg H, Jansen G (2018) Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model. PLoS Biol 16:e2004356. https:\/\/doi.org\/10.1371\/journal.pbio.2004356","journal-title":"PLoS Biol"},{"key":"4980_CR20","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1007\/s00253-021-11695-z","volume":"105","author":"K Bhargava","year":"2021","unstructured":"Bhargava K, Nath G, Bhargava A, Aseri G, Jain N (2021) Phage therapeutics: from promises to practices and prospectives. Appl Microbiol Biotechnol 105:9047\u20139067. https:\/\/doi.org\/10.1007\/s00253-021-11695-z","journal-title":"Appl Microbiol Biotechnol"},{"key":"4980_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nature15254","volume":"526","author":"J Bondy-Denomy","year":"2015","unstructured":"Bondy-Denomy J et al (2015) Multiple mechanisms for CRISPR\u2013Cas inhibition by anti-CRISPR proteins. Nature 526:136\u2013139. https:\/\/doi.org\/10.1038\/nature15254","journal-title":"Nature"},{"key":"4980_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-virology-101416-041616","volume":"4","author":"AL Borges","year":"2017","unstructured":"Borges AL, Davidson AR, Bondy-Denomy J (2017) The discovery, mechanisms, and evolutionary impact of anti-CRISPRs. Annu Rev Virol 4:37\u201359. https:\/\/doi.org\/10.1146\/annurev-virology-101416-041616","journal-title":"Annu Rev Virol"},{"key":"4980_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12916-017-0910-9","volume":"15","author":"J Borysowski","year":"2017","unstructured":"Borysowski J, Ehni HJ, G\u00f3rski A (2017) Ethics review in compassionate use. BMC Med 15:136. https:\/\/doi.org\/10.1186\/s12916-017-0910-9","journal-title":"BMC Med"},{"key":"4980_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiag096","volume":"13","author":"K Bosco","year":"2026","unstructured":"Bosco K, Fabijan AP, Iredell J, Dabrowska K, Khatami A (2026) Immune responses to phage therapy in humans: a review. J Infect Dis 13:jiag096. https:\/\/doi.org\/10.1093\/infdis\/jiag096","journal-title":"J Infect Dis"},{"key":"4980_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41564-026-02280-z","volume":"11","author":"MA Brockhurst","year":"2026","unstructured":"Brockhurst MA, Fothergill JL, van Houte S, Westra ER (2026) Realizing phage therapy in the UK. Nat Microbiol 11:619\u2013621. https:\/\/doi.org\/10.1038\/s41564-026-02280-z","journal-title":"Nat Microbiol"},{"key":"4980_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10060672","volume":"10","author":"A Broncano-Lavado","year":"2021","unstructured":"Broncano-Lavado A, Santamar\u00eda-Corral G, Esteban J, Garc\u00eda-Quintanilla M (2021) Advances in bacteriophage therapy against relevant multidrug-resistant pathogens. Antibiotics 10:672. https:\/\/doi.org\/10.3390\/antibiotics10060672","journal-title":"Antibiotics"},{"key":"4980_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s40484-017-0094-5","volume":"5","author":"R Brown","year":"2017","unstructured":"Brown R, Lengeling A, Wang B (2017) Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. Quant Biol 5:42\u201354. https:\/\/doi.org\/10.1007\/s40484-017-0094-5","journal-title":"Quant Biol"},{"key":"4980_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011602","volume":"19","author":"J Bulssico","year":"2023","unstructured":"Bulssico J, Papukashvili I, Espinosa L, Gandon S, Ansaldi M (2023) Phage-antibiotic synergy: cell filamentation is a key driver of successful phage predation. PLoS Pathog 19:e1011602. https:\/\/doi.org\/10.1371\/journal.ppat.1011602","journal-title":"PLoS Pathog"},{"key":"4980_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-22075-2","volume":"15","author":"PY Camejo","year":"2025","unstructured":"Camejo PY et al (2025) A machine learning approach to predict strain-specific phage-host interactions. Sci Rep 15:38249. https:\/\/doi.org\/10.1038\/s41598-025-22075-2","journal-title":"Sci Rep"},{"key":"4980_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7120625","volume":"7","author":"A Carroll-Portillo","year":"2019","unstructured":"Carroll-Portillo A, Lin HC (2019) Bacteriophage and the innate immune system: access and signaling. Microorganisms 7:625. https:\/\/doi.org\/10.3390\/microorganisms7120625","journal-title":"Microorganisms"},{"key":"4980_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.23.22283996","author":"B Chan","year":"2023","unstructured":"Chan B et al (2023) Personalized inhaled bacteriophage therapy decreases multidrug-resistant Pseudomonas aeruginosa. MedRxiv:2023 \u2013 2001. https:\/\/doi.org\/10.1101\/2023.01.23.22283996","journal-title":"MedRxiv:2023 \u2013 2001"},{"key":"4980_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry WN, Concepcion-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR (2017) Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One 12:e0168615. https:\/\/doi.org\/10.1371\/journal.pone.0168615","journal-title":"PLoS One"},{"key":"4980_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/jtccm-d-24-00022","volume":"6","author":"J Chen","year":"2024","unstructured":"Chen J, Huang M (2024) The application value of bacteriophage in patients with severe drug-resistant bacterial infections. J Transl Crit Care Med 6:e24-00022. https:\/\/doi.org\/10.1097\/jtccm-d-24-00022","journal-title":"J Transl Crit Care Med"},{"key":"4980_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5582\/bst.2022.01147","volume":"16","author":"P Chen","year":"2022","unstructured":"Chen P et al (2022) Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci Trends 16:158\u2013162. https:\/\/doi.org\/10.5582\/bst.2022.01147","journal-title":"Biosci Trends"},{"key":"4980_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","volume":"10","author":"R Chen","year":"2025","unstructured":"Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D (2025) Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther 10:216. https:\/\/doi.org\/10.1038\/s41392-025-02264-1","journal-title":"Signal Transduct Target Ther"},{"key":"4980_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.mib.2014.05.022","volume":"19","author":"RJ Citorik","year":"2014","unstructured":"Citorik RJ, Mimee M, Lu TK (2014) Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol 19:59\u201369. https:\/\/doi.org\/10.1016\/j.mib.2014.05.022","journal-title":"Curr Opin Microbiol"},{"key":"4980_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4161\/bact.1.1.14942","volume":"1","author":"MR Clokie","year":"2011","unstructured":"Clokie MR, Millard AD, Letarov AV, Heaphy S (2011) Phages in nature. Bacteriophage 1:31\u201345. https:\/\/doi.org\/10.4161\/bact.1.1.14942","journal-title":"Bacteriophage"},{"key":"4980_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000799","volume":"2","author":"AM Comeau","year":"2007","unstructured":"Comeau AM, T\u00e9tart F, Trojet SN, Pr\u00e8re M-F, Krisch H (2007) Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2:e799. https:\/\/doi.org\/10.1371\/journal.pone.0000799","journal-title":"PLoS One"},{"key":"4980_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S1466252319000161","volume":"21","author":"M Dec","year":"2020","unstructured":"Dec M, Wernicki A, Urban-Chmiel R (2020) Efficacy of experimental phage therapies in livestock. Anim Health Res Rev 21:69\u201383. https:\/\/doi.org\/10.1017\/S1466252319000161","journal-title":"Anim Health Res Rev"},{"key":"4980_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25:730\u2013733. https:\/\/doi.org\/10.1038\/s41591-019-0437-z","journal-title":"Nat Med"},{"key":"4980_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick RM et al (2023) Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin Infect Dis 76:103\u2013112. https:\/\/doi.org\/10.1093\/cid\/ciac453","journal-title":"Clin Infect Dis"},{"key":"4980_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/infdis\/jiac219","volume":"226","author":"HW Dolby","year":"2022","unstructured":"Dolby HW, Clifford SA, Laurenson IF, Fowler VG Jr., Russell CD (2022) Heterogeneity in Staphylococcus aureus bacteraemia clinical trials complicates interpretation of findings. J Infect Dis 226:723\u2013728. https:\/\/doi.org\/10.1093\/infdis\/jiac219","journal-title":"J Infect Dis"},{"key":"4980_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1611857","volume":"15","author":"MB Doud","year":"2025","unstructured":"Doud MB, Robertson JM, Strathdee SA (2025) Optimizing phage therapy with artificial intelligence: a perspective. Front Cell Infect Microbiol 15:1611857. https:\/\/doi.org\/10.3389\/fcimb.2025.1611857","journal-title":"Front Cell Infect Microbiol"},{"key":"4980_CR44","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12551-017-0382-3","volume":"10","author":"AS Dowah","year":"2018","unstructured":"Dowah AS, Clokie MR (2018) Review of the nature, diversity and structure of bacteriophage receptor binding proteins that target Gram-positive bacteria. Biophy Rev 10:535\u2013542. https:\/\/doi.org\/10.1007\/s12551-017-0382-3","journal-title":"Biophy Rev"},{"key":"4980_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/1120009x.2025.2547147","author":"A Elfadadny","year":"2025","unstructured":"Elfadadny A et al (2025) Bacteriophage therapy in clinical practice: case studies of Pseudomonas aeruginosa infections. J Chemother. https:\/\/doi.org\/10.1080\/1120009x.2025.2547147","journal-title":"J Chemother"},{"key":"4980_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00296","volume":"8","author":"L Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez L, Guti\u00e9rrez D, Rodr\u00edguez A, Garc\u00eda P (2018) Application of bacteriophages in the agro-food sector: a long way toward approval. Front Cell Infect Microbiol 8:296. https:\/\/doi.org\/10.3389\/fcimb.2018.00296","journal-title":"Front Cell Infect Microbiol"},{"key":"4980_CR47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10096-025-05375-3","volume":"45","author":"L Fern\u00e1ndez-Garcia","year":"2026","unstructured":"Fern\u00e1ndez-Garcia L et al (2026) Phages and quorum sensing: findings to consider in phage therapy. Eur J Clin Microbiol Infect Dis 45:615\u2013629. https:\/\/doi.org\/10.1007\/s10096-025-05375-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4980_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/app16042002","volume":"16","author":"MP Ferraz","year":"2026","unstructured":"Ferraz MP (2026) Phage therapy for bone and joint infections: challenges, biological dynamics, and therapeutic prospects in the era of antimicrobial resistance. Appl Sci (Basel) 16:2002. https:\/\/doi.org\/10.3390\/app16042002","journal-title":"Appl Sci (Basel)"},{"key":"4980_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.569159","volume":"8","author":"T Ferry","year":"2021","unstructured":"Ferry T et al (2021) Case report: arthroscopic \u201cDebridement Antibiotics and Implant Retention\u201d with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosa prosthetic knee infection. Front Med 8:2021. https:\/\/doi.org\/10.3389\/fmed.2021.569159","journal-title":"Front Med"},{"key":"4980_CR50","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.12968\/jowc.2016.25.Sup7.S27","volume":"25","author":"R Fish","year":"2016","unstructured":"Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S (2016) Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 25:S27\u2013S33. https:\/\/doi.org\/10.12968\/jowc.2016.25.Sup7.S27","journal-title":"J Wound Care"},{"key":"4980_CR51","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/antibiotics9110827","volume":"9","author":"A G\u00f3rski","year":"2020","unstructured":"G\u00f3rski A, Borysowski J, Mi\u0119dzybrodzki R (2020) Phage therapy: towards a successful clinical trial. Antibiotics 9:827. https:\/\/doi.org\/10.3390\/antibiotics9110827","journal-title":"Antibiotics"},{"key":"4980_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2025.100436","volume":"8","author":"O Grari","year":"2025","unstructured":"Grari O et al (2025) A comprehensive review on biofilm-associated infections: mechanisms, diagnostic challenges, and innovative therapeutic strategies. Microbe 8:100436. https:\/\/doi.org\/10.1016\/j.microb.2025.100436","journal-title":"Microbe"},{"key":"4980_CR53","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/ciy947","volume":"69","author":"L El Haddad","year":"2018","unstructured":"El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF (2018) A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin Infect Dis 69:167\u2013178. https:\/\/doi.org\/10.1093\/cid\/ciy947","journal-title":"Clin Infect Dis"},{"key":"4980_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton E, Locascio JJ (2018) Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 125:1716. https:\/\/doi.org\/10.1111\/1471-0528.15199","journal-title":"BJOG"},{"key":"4980_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.coviro.2011.06.009","volume":"1","author":"GF Hatfull","year":"2011","unstructured":"Hatfull GF, Hendrix RW (2011) Bacteriophages and their genomes. Curr Opin Virol 1:298\u2013303. https:\/\/doi.org\/10.1016\/j.coviro.2011.06.009","journal-title":"Curr Opin Virol"},{"key":"4980_CR56","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4155\/tde-2017-0040","volume":"8","author":"H Hathaway","year":"2017","unstructured":"Hathaway H, Milo S, Sutton JM, Jenkins TA (2017) Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins. Ther Deliv 8:543\u2013556. https:\/\/doi.org\/10.4155\/tde-2017-0040","journal-title":"Ther Deliv"},{"key":"4980_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/srep14802","volume":"5","author":"K Hodyra-Stefaniak","year":"2015","unstructured":"Hodyra-Stefaniak K et al (2015) Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep 5:14802. https:\/\/doi.org\/10.1038\/srep14802","journal-title":"Sci Rep"},{"key":"4980_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050556","volume":"10","author":"D Holger","year":"2021","unstructured":"Holger D, Kebriaei R, Morrisette T, Lev K, Alexander J, Rybak M (2021) Clinical pharmacology of bacteriophage therapy: A focus on multidrug-resistant Pseudomonas aeruginosa infections. Antibiotics Basel 10:556. https:\/\/doi.org\/10.3390\/antibiotics10050556","journal-title":"Antibiotics Basel"},{"key":"4980_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","volume":"70","author":"P Hyman","year":"2010","unstructured":"Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217\u2013248. https:\/\/doi.org\/10.1016\/S0065-2164(10)70007-1","journal-title":"Adv Appl Microbiol"},{"key":"4980_CR60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault P et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect Dis 19:35\u201345. https:\/\/doi.org\/10.1016\/S1473-3099(18)30482-1","journal-title":"Lancet Infect Dis"},{"key":"4980_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1172635","volume":"14","author":"H-J Jia","year":"2023","unstructured":"Jia H-J, Jia P-P, Yin S, Bu L-K, Yang G, Pei D-S (2023) Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions. Front Microbiol 14:1172635. https:\/\/doi.org\/10.3389\/fmicb.2023.1172635","journal-title":"Front Microbiol"},{"key":"4980_CR62","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10068-016-0192-6","volume":"25","author":"A Jo","year":"2016","unstructured":"Jo A, Kim J, Ding T, Ahn J (2016) Role of phage-antibiotic combination in reducing antibiotic resistance in Staphylococcus aureus. Food Sci Biotechnol 25:1211\u20131215. https:\/\/doi.org\/10.1007\/s10068-016-0192-6","journal-title":"Food Sci Biotechnol"},{"key":"4980_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuaf061","volume":"50","author":"T Kaneko","year":"2025","unstructured":"Kaneko T, Nakatsuka K, Tsuneda S (2025) Phage cocktails: state-of-the-art technologies and strategies for effective design. FEMS Microbiol Rev 50:fuaf061. https:\/\/doi.org\/10.1093\/femsre\/fuaf061","journal-title":"FEMS Microbiol Rev"},{"key":"4980_CR64","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s13205-024-04101-8","volume":"14","author":"A Kapoor","year":"2024","unstructured":"Kapoor A, Mudaliar SB, Bhat VG, Chakraborty I, Prasad ASB, Mazumder N (2024) Phage therapy: a novel approach against multidrug-resistant pathogens. 3 Biotech 14:256. https:\/\/doi.org\/10.1007\/s13205-024-04101-8","journal-title":"3 Biotech"},{"key":"4980_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/bies.201400152","volume":"37","author":"EC Keen","year":"2015","unstructured":"Keen EC (2015) A century of phage research: bacteriophages and the shaping of modern biology. Bioessays 37:6\u20139. https:\/\/doi.org\/10.1002\/bies.201400152","journal-title":"Bioessays"},{"key":"4980_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-020-01891-8","volume":"20","author":"LG Kifelew","year":"2020","unstructured":"Kifelew LG et al (2020) Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. BMC Microbiol 20:204. https:\/\/doi.org\/10.1186\/s12866-020-01891-8","journal-title":"BMC Microbiol"},{"key":"4980_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187996","volume":"135","author":"MK Kim","year":"2025","unstructured":"Kim MK et al (2025) Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches. J Clin Invest 135:e187996. https:\/\/doi.org\/10.1172\/JCI187996","journal-title":"J Clin Invest"},{"key":"4980_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.701898","volume":"12","author":"P Knezevic","year":"2021","unstructured":"Knezevic P, Hoyle NS, Matsuzaki S, Gorski A (2021) Advances in phage therapy: present challenges and future perspectives. Front Microbiol 12:701898. https:\/\/doi.org\/10.3389\/fmicb.2021.701898","journal-title":"Front Microbiol"},{"key":"4980_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.658374","volume":"12","author":"KE Kortright","year":"2021","unstructured":"Kortright KE, Doss-Gollin S, Chan BK, Turner PE (2021) Evolution of bacterial cross-resistance to lytic phages and albicidin antibiotic. Front Microbiol 12:658374. https:\/\/doi.org\/10.3389\/fmicb.2021.658374","journal-title":"Front Microbiol"},{"key":"4980_CR70","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrmicro2315","volume":"8","author":"SJ Labrie","year":"2010","unstructured":"Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317\u2013327. https:\/\/doi.org\/10.1038\/nrmicro2315","journal-title":"Nat Rev Microbiol"},{"key":"4980_CR71","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s00253-017-8224-6","volume":"101","author":"A Latka","year":"2017","unstructured":"Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z (2017) Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol 101:3103\u20133119. https:\/\/doi.org\/10.1007\/s00253-017-8224-6","journal-title":"Appl Microbiol Biotechnol"},{"key":"4980_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy064","volume":"5","author":"S LaVergne","year":"2018","unstructured":"LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley RT, Wooten D (2018) Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect Dis 5:ofy064. https:\/\/doi.org\/10.1093\/ofid\/ofy064","journal-title":"Open Forum Infect Dis"},{"key":"4980_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.2022.e1010746","volume":"18","author":"QJ Leclerc","year":"2022","unstructured":"Leclerc QJ, Lindsay JA, Knight GM (2022) Modelling the synergistic effect of bacteriophage and antibiotics on bacteria: killers and drivers of resistance evolution. PLoS Comput Biol 18:e1010746. https:\/\/doi.org\/10.1371\/journal.pcbi.2022.e1010746","journal-title":"PLoS Comput Biol"},{"key":"4980_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2388-7","volume":"19","author":"DMC Leite","year":"2018","unstructured":"Leite DMC, Brochet X, Resch G, Que Y-A, Neves A, Pe\u00f1a-Reyes C (2018) Computational prediction of inter-species relationships through omics data analysis and machine learning. BMC Bioinformatics 19:420. https:\/\/doi.org\/10.1186\/s12859-018-2388-7","journal-title":"BMC Bioinformatics"},{"key":"4980_CR75","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-virology-092917-043544","volume":"5","author":"S Lemire","year":"2018","unstructured":"Lemire S, Yehl KM, Lu TK (2018) Phage-Based Applications in Synthetic Biology. Annu Rev Virol 5:453\u2013476. https:\/\/doi.org\/10.1146\/annurev-virology-092917-043544","journal-title":"Annu Rev Virol"},{"key":"4980_CR76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12223-009-0064-z","volume":"54","author":"S Letkiewicz","year":"2009","unstructured":"Letkiewicz S, Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, G\u00f3rski A (2009) Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis\u2013case report. Folia Microbiol 54:457\u2013461. https:\/\/doi.org\/10.1007\/s12223-009-0064-z","journal-title":"Folia Microbiol"},{"key":"4980_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11010024","volume":"11","author":"G Li","year":"2022","unstructured":"Li G, Walker MJ, De Oliveira DMP (2022) Vancomycin resistance in Enterococcus and Staphylococcus aureus. Microorganisms 11:24. https:\/\/doi.org\/10.3390\/microorganisms11010024","journal-title":"Microorganisms"},{"key":"4980_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29689-4","volume":"13","author":"JS Little","year":"2022","unstructured":"Little JS et al (2022) Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat Commun 13:2313. https:\/\/doi.org\/10.1038\/s41467-022-29689-4","journal-title":"Nat Commun"},{"key":"4980_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00919-1","volume":"30","author":"H Liu","year":"2023","unstructured":"Liu H, Hu Z, Li M, Yang Y, Lu S, Rao X (2023) Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. J Biomed Sci 30:29. https:\/\/doi.org\/10.1186\/s12929-023-00919-1","journal-title":"J Biomed Sci"},{"key":"4980_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-021-00480-z","volume":"35","author":"M \u0141obocka","year":"2021","unstructured":"\u0141obocka M, D\u0105browska K, G\u00f3rski A (2021) Engineered bacteriophage therapeutics: rationale, challenges and future. BioDrugs 35:255\u2013280. https:\/\/doi.org\/10.1007\/s40259-021-00480-z","journal-title":"BioDrugs"},{"key":"4980_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070820","volume":"17","author":"AN Mafe","year":"2025","unstructured":"Mafe AN, B\u00fcsselberg D (2025) Phage therapy in managing multidrug-resistant (MDR) infections in cancer therapy: innovations, complications, and future directions. Pharmaceutics 17:820. https:\/\/doi.org\/10.3390\/pharmaceutics17070820","journal-title":"Pharmaceutics"},{"key":"4980_CR82","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fmicb.2019.00574","volume":"10","author":"P Manohar","year":"2019","unstructured":"Manohar P, Tamhankar AJ, Lundborg CS, Nhachimuthu R (2019) Therapeutic characterization and efficacy of bacteriophage cocktails infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Front Microbiol 10:574. https:\/\/doi.org\/10.3389\/fmicb.2019.00574","journal-title":"Front Microbiol"},{"key":"4980_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08621-1","volume":"23","author":"G Mboowa","year":"2023","unstructured":"Mboowa G (2023) Reviewing the journey to the clinical application of bacteriophages to treat multi-drug-resistant bacteria. BMC Infect Dis 23:654. https:\/\/doi.org\/10.1186\/s12879-023-08621-1","journal-title":"BMC Infect Dis"},{"key":"4980_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/v11040343","volume":"11","author":"S McCallin","year":"2019","unstructured":"McCallin S, Sacher JC, Zheng J, Chan BK (2019) Current state of compassionate phage therapy. Viruses 11:343. https:\/\/doi.org\/10.3390\/v11040343","journal-title":"Viruses"},{"key":"4980_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285824","volume":"18","author":"S McCammon","year":"2023","unstructured":"McCammon S, Makarovs K, Banducci S, Gold V (2023) Phage therapy and the public: increasing awareness essential to widespread use. PLoS One 18:e0285824. https:\/\/doi.org\/10.1371\/journal.pone.0285824","journal-title":"PLoS One"},{"key":"4980_CR86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/1040841X.2020.1729695","volume":"46","author":"LD Melo","year":"2020","unstructured":"Melo LD, Oliveira H, Pires DP, Dabrowska K, Azeredo J (2020) Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol 46:78\u201399. https:\/\/doi.org\/10.1080\/1040841X.2020.1729695","journal-title":"Crit Rev Microbiol"},{"key":"4980_CR87","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmi.2023.01.011","volume":"29","author":"W-J Metsemakers","year":"2023","unstructured":"Metsemakers W-J et al (2023) Bacteriophage therapy for human musculoskeletal and skin\/soft tissue infections. Clin Microbiol Infect 29:695\u2013701. https:\/\/doi.org\/10.1016\/j.cmi.2023.01.011","journal-title":"Clin Microbiol Infect"},{"key":"4980_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.emcon.2024.100389","volume":"10","author":"R Mithuna","year":"2024","unstructured":"Mithuna R et al (2024) Emergence of antibiotic resistance due to the excessive use of antibiotics in medicines and feed additives: a global scenario with emphasis on the Indian perspective. Emerg Contam 10:100389. https:\/\/doi.org\/10.1016\/j.emcon.2024.100389","journal-title":"Emerg Contam"},{"key":"4980_CR89","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"4980_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36034-2","volume":"13","author":"A Naknaen","year":"2023","unstructured":"Naknaen A, Samernate T, Wannasrichan W, Surachat K, Nonejuie P, Chaikeeratisak V (2023) Combination of genetically diverse Pseudomonas phages enhances the cocktail efficiency against bacteria. Sci Rep 13:8921. https:\/\/doi.org\/10.1038\/s41598-023-36034-2","journal-title":"Sci Rep"},{"key":"4980_CR91","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick JA et al (2022) Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185:1860\u20131874. https:\/\/doi.org\/10.1016\/j.cell.2022.04.024","journal-title":"Cell"},{"key":"4980_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128231","volume":"298","author":"X Nie","year":"2025","unstructured":"Nie X, Tong Y, Li M, Ning Z, Fan H (2025) Bacteriophage therapy for critical antibiotic-resistant Gram-positive bacteria: a systematic review of clinical researches. Microbiol Res 298:128231. https:\/\/doi.org\/10.1016\/j.micres.2025.128231","journal-title":"Microbiol Res"},{"key":"4980_CR93","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/03009734.2014.902878","volume":"119","author":"AS Nilsson","year":"2014","unstructured":"Nilsson AS (2014) Phage therapy-constraints and possibilities. Upsala J Med Sci 119:192\u2013198. https:\/\/doi.org\/10.3109\/03009734.2014.902878","journal-title":"Upsala J Med Sci"},{"key":"4980_CR94","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/03009734.2019.1688433","volume":"124","author":"AS Nilsson","year":"2019","unstructured":"Nilsson AS (2019) Pharmacological limitations of phage therapy. Upsala J Med Sci 124:218\u2013227. https:\/\/doi.org\/10.1080\/03009734.2019.1688433","journal-title":"Upsala J Med Sci"},{"key":"4980_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/v10070351","author":"F Oechslin","year":"2018","unstructured":"Oechslin F (2018) Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. https:\/\/doi.org\/10.3390\/v10070351","journal-title":"Viruses"},{"key":"4980_CR96","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/infdis\/jiw632","volume":"215","author":"F Oechslin","year":"2017","unstructured":"Oechslin F et al (2017) Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis 215:703\u2013712. https:\/\/doi.org\/10.1093\/infdis\/jiw632","journal-title":"J Infect Dis"},{"key":"4980_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1071\/MA24022","volume":"45","author":"AD Ogunniyi","year":"2024","unstructured":"Ogunniyi AD, Venter H, Blaskovich MA (2024) New antibiotics to combat One Health AMR. Microbiol Aust 45:74\u201378. https:\/\/doi.org\/10.1071\/MA24022","journal-title":"Microbiol Aust"},{"key":"4980_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.107088","volume":"197","author":"DB Olawade","year":"2024","unstructured":"Olawade DB et al (2024) Phage therapy: a targeted approach to overcoming antibiotic resistance. Microb Pathog 197:107088. https:\/\/doi.org\/10.1016\/j.micpath.2024.107088","journal-title":"Microb Pathog"},{"key":"4980_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/v11010018","volume":"11","author":"O Patey","year":"2018","unstructured":"Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A (2018) Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. Viruses 11:18. https:\/\/doi.org\/10.3390\/v11010018","journal-title":"Viruses"},{"key":"4980_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002119","volume":"21","author":"A Petrovic Fabijan","year":"2023","unstructured":"Petrovic Fabijan A, Iredell J, Danis-Wlodarczyk K, Kebriaei R, Abedon ST (2023) Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol 21:e3002119. https:\/\/doi.org\/10.1371\/journal.pbio.3002119","journal-title":"PLoS Biol"},{"key":"4980_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124280","volume":"10","author":"NB Pincus","year":"2015","unstructured":"Pincus NB, Reckhow JD, Saleem D, Jammeh ML, Datta SK, Myles IA (2015) Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection. PLoS One 10:e0124280. https:\/\/doi.org\/10.1371\/journal.pone.0124280","journal-title":"PLoS One"},{"key":"4980_CR102","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","volume":"44","author":"DP Pires","year":"2020","unstructured":"Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J (2020) Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 44:684\u2013700. https:\/\/doi.org\/10.1093\/femsre\/fuaa017","journal-title":"FEMS Microbiol Rev"},{"key":"4980_CR103","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s11095-014-1617-7","volume":"32","author":"JP Pirnay","year":"2015","unstructured":"Pirnay JP et al (2015a) Quality and safety requirements for sustainable phage therapy products. Pharm Res 32:2173\u20132179. https:\/\/doi.org\/10.1007\/s11095-014-1617-7","journal-title":"Pharm Res"},{"key":"4980_CR104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/9781681081403115010005","volume-title":"The Challenging of Antibiotic Resistance in the Development of New Therapeutics","author":"JP Pirnay","year":"2015","unstructured":"Pirnay JP (2015b) Bacteriophages as Antibacterial Agents: Why are We Facing an Antibiotic Crisis and How Could Bacteriophages be of Help? The Challenging of Antibiotic Resistance in the Development of New Therapeutics, vol vol 23. Bentham Science Publishers, 10-32. https:\/\/doi.org\/10.2174\/9781681081403115010005"},{"key":"4980_CR105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-1-0716-3523-0_6","volume":"2734","author":"JP Pirnay","year":"2024","unstructured":"Pirnay JP, Merabishvili M, De Vos D, Verbeken G (2024) Bacteriophage Production in Compliance with Regulatory Requirements. Methods Mol Biol 2734:89\u2013115. https:\/\/doi.org\/10.1007\/978-1-0716-3523-0_6","journal-title":"Methods Mol Biol"},{"key":"4980_CR106","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/infdis\/jiab112","volume":"225","author":"J Prazak","year":"2022","unstructured":"Prazak J et al (2022) Benefits of aerosolized phages for the treatment of pneumonia due to methicillin-resistant Staphylococcus aureus: an experimental study in rats. J Infect Dis 225:1452\u20131459. https:\/\/doi.org\/10.1093\/infdis\/jiab112","journal-title":"J Infect Dis"},{"key":"4980_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00513","volume":"10","author":"N Principi","year":"2019","unstructured":"Principi N, Silvestri E, Esposito S (2019) Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol 10:513. https:\/\/doi.org\/10.3389\/fphar.2019.00513","journal-title":"Front Pharmacol"},{"key":"4980_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01056-1","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S et al (2022) Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther 7:199. https:\/\/doi.org\/10.1038\/s41392-022-01056-1","journal-title":"Signal Transduct Target Ther"},{"key":"4980_CR109","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70629","volume":"16","author":"K Sahoo","year":"2024","unstructured":"Sahoo K, Meshram S (2024) Biofilm formation in chronic infections: a comprehensive review of pathogenesis, clinical implications, and novel therapeutic approaches. Cureus 16:e70629. https:\/\/doi.org\/10.7759\/cureus.70629","journal-title":"Cureus"},{"key":"4980_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131946","volume":"11","author":"MA Salam","year":"2023","unstructured":"Salam MA et al (2023) Antimicrobial resistance: a growing serious threat for global public health. Healthcare Basel 11:1946. https:\/\/doi.org\/10.3390\/healthcare11131946","journal-title":"Healthcare Basel"},{"key":"4980_CR111","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrmicro3096","volume":"11","author":"JE Samson","year":"2013","unstructured":"Samson JE, Magad\u00e1n AH, Sabri M, Moineau S (2013) Revenge of the phages: defeating bacterial defences. Nat Rev Microbiol 11:675\u2013687. https:\/\/doi.org\/10.1038\/nrmicro3096","journal-title":"Nat Rev Microbiol"},{"key":"4980_CR112","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MTBP-0016-2017","volume":"5","author":"A San Millan","year":"2017","unstructured":"San Millan A, MacLean RC (2017) Fitness costs of plasmids: a limit to plasmid transmission. Microbiol Spectr 5:10.1128\/microbiolspec. mtbp-0016-2017. https:\/\/doi.org\/10.1128\/microbiolspec.MTBP-0016-2017","journal-title":"Microbiol Spectr"},{"key":"4980_CR113","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2475067","volume":"2016","author":"S Santajit","year":"2016","unstructured":"Santajit S, Indrawattana N (2016) Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Res Int 2016:2475067. https:\/\/doi.org\/10.1155\/2016\/2475067","journal-title":"BioMed Res Int"},{"key":"4980_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071089","volume":"12","author":"G Santamar\u00eda-Corral","year":"2023","unstructured":"Santamar\u00eda-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, Garc\u00eda-Quintanilla M (2023) Bacteriophage\u2013antibiotic combination therapy against Pseudomonas aeruginosa. Antibiotics Basel 12:1089. https:\/\/doi.org\/10.3390\/antibiotics12071089","journal-title":"Antibiotics Basel"},{"key":"4980_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1095860","volume":"13","author":"S Sarp","year":"2022","unstructured":"Sarp S, Reichenbach R, Aliu P (2022) An approach to data collection in compassionate use\/managed access. Front Pharmacol 13:1095860. https:\/\/doi.org\/10.3389\/fphar.2022.1095860","journal-title":"Front Pharmacol"},{"key":"4980_CR116","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/fmb.12.97","volume":"7","author":"M Schmelcher","year":"2012","unstructured":"Schmelcher M, Donovan DM, Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7:1147\u20131171. https:\/\/doi.org\/10.2217\/fmb.12.97","journal-title":"Future Microbiol"},{"key":"4980_CR117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-41986-2_4","volume-title":"Bacteriophages","author":"CL Schneider","year":"2021","unstructured":"Schneider CL (2021) Bacteriophage-mediated horizontal gene transfer: transduction. Bacteriophages. Springer, pp 151\u2013192. https:\/\/doi.org\/10.1007\/978-3-319-41986-2_4"},{"key":"4980_CR118","doi-asserted-by":"publisher","DOI":"10.1128\/aac","author":"RT Schooley","year":"2017","unstructured":"Schooley RT et al (2017) Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac","journal-title":"Antimicrob Agents Chemother"},{"key":"4980_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13010100","volume":"13","author":"N Segundo-Arizmendi","year":"2025","unstructured":"Segundo-Arizmendi N, Arellano-Maciel D, Rivera-Ram\u00edrez A, Pi\u00f1a-Gonz\u00e1lez AM, L\u00f3pez-Leal G, Hern\u00e1ndez-Baltazar E (2025) Bacteriophages: a challenge for antimicrobial therapy. Microorganisms 13:100. https:\/\/doi.org\/10.3390\/microorganisms13010100","journal-title":"Microorganisms"},{"key":"4980_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2025.100356","volume":"7","author":"S Sharif","year":"2025","unstructured":"Sharif S, Yadav AK (2025) Bacterial biofilm and its role in antibiotic resistance. Microbe 7:100356. https:\/\/doi.org\/10.1016\/j.microb.2025.100356","journal-title":"Microbe"},{"key":"4980_CR121","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/v11100954","volume":"11","author":"M Shlezinger","year":"2019","unstructured":"Shlezinger M, Coppenhagen-Glazer S, Gelman D, Beyth N, Hazan R (2019) Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin. Viruses 11:954. https:\/\/doi.org\/10.3390\/v11100954","journal-title":"Viruses"},{"key":"4980_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1292618","volume":"14","author":"NM Smith","year":"2023","unstructured":"Smith NM et al (2023) A mechanism-based pathway toward administering highly active N-phage cocktails. Front Microbiol 14:1292618. https:\/\/doi.org\/10.3389\/fmicb.2023.1292618","journal-title":"Front Microbiol"},{"key":"4980_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101340","volume":"11","author":"HJ Stacey","year":"2022","unstructured":"Stacey HJ, De Soir S, Jones JD (2022) The safety and efficacy of phage therapy: a systematic review of clinical and safety trials. Antibiotics 11:1340. https:\/\/doi.org\/10.3390\/antibiotics11101340","journal-title":"Antibiotics"},{"key":"4980_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.724767","volume":"12","author":"KM Styles","year":"2021","unstructured":"Styles KM, Brown AT, Sagona AP (2021) A review of using mathematical modeling to improve our understanding of bacteriophage, bacteria, and eukaryotic interactions. Front Microbiol 12:724767. https:\/\/doi.org\/10.3389\/fmicb.2021.724767","journal-title":"Front Microbiol"},{"key":"4980_CR125","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1038\/s41564-025-02130-4","volume":"10","author":"D Subedi","year":"2025","unstructured":"Subedi D et al (2025) Rational design of a hospital-specific phage cocktail to treat Enterobacter cloacae complex infections. Nat Microbiol 10:2702\u20132719. https:\/\/doi.org\/10.1038\/s41564-025-02130-4","journal-title":"Nat Microbiol"},{"key":"4980_CR126","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA et al (2022) Considerations for the use of phage therapy in clinical practice. Antimicrob Agents Chemother 66:e02071-02021. https:\/\/doi.org\/10.1128\/AAC.02071-21","journal-title":"Antimicrob Agents Chemother"},{"key":"4980_CR127","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3109\/07853890108995959","volume":"33","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Morris JG (2001) Bacteriophages as therapeutic agents. Ann Med 33:507\u2013509. https:\/\/doi.org\/10.3109\/07853890108995959","journal-title":"Ann Med"},{"key":"4980_CR128","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","volume":"45","author":"A Sulakvelidze","year":"2001","unstructured":"Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649\u2013659. https:\/\/doi.org\/10.1128\/AAC.45.3.649-659.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"4980_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-07047-5","volume":"23","author":"PD Tamma","year":"2022","unstructured":"Tamma PD et al (2022) Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial. Trials 23:1057. https:\/\/doi.org\/10.1186\/s13063-022-07047-5","journal-title":"Trials"},{"key":"4980_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106628","volume":"9","author":"C Torres-Barcel\u00f3","year":"2014","unstructured":"Torres-Barcel\u00f3 C, Arias-S\u00e1nchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME (2014) A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One 9:e106628. https:\/\/doi.org\/10.1371\/journal.pone.0106628","journal-title":"PLoS One"},{"key":"4980_CR131","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","volume":"22","author":"S Uyttebroek","year":"2022","unstructured":"Uyttebroek S et al (2022) Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis 22:e208\u2013e220. https:\/\/doi.org\/10.1016\/S1473-3099(21)00612-5","journal-title":"Lancet Infect Dis"},{"key":"4980_CR132","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-030-21862-1_3","volume-title":"Horizontal Gene Transfer: Breaking Borders Between Living Kingdoms","author":"TG Villa","year":"2019","unstructured":"Villa TG, Feijoo-Siota L, Rama JR, S\u00e1nchez-P\u00e9rez A, Vi\u00f1as M (2019) Horizontal gene transfer between bacteriophages and bacteria: antibiotic resistances and toxin production. Horizontal Gene Transfer: Breaking Borders Between Living Kingdoms. Springer, pp 97\u2013142. https:\/\/doi.org\/10.1007\/978-3-030-21862-1_3"},{"key":"4980_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534717","volume":"33","author":"N Walter","year":"2023","unstructured":"Walter N, Mirzaei M, Deng L, Willy C, Alt V, Rupp M (2023) The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections. Med Princ Pract 33:1\u20139. https:\/\/doi.org\/10.1159\/000534717","journal-title":"Med Princ Pract"},{"key":"4980_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025a.128230","volume":"298","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang S, Ahn J (2025a) Bridging phage production models and practical applications to control antibiotic-resistant bacteria. Microbiol Res 298:128230. https:\/\/doi.org\/10.1016\/j.micres.2025a.128230","journal-title":"Microbiol Res"},{"key":"4980_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14111134","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li L, Liang Y, Xu K, Ye Y, He M (2025b) Phage therapy for Acinetobacter baumannii infections: a review on advances in classification, applications, and translational roadblocks. Antibiotics 14:134. https:\/\/doi.org\/10.3390\/antibiotics14111134","journal-title":"Antibiotics"},{"key":"4980_CR136","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","volume":"34","author":"A Wright","year":"2009","unstructured":"Wright A, Hawkins CH, Angg\u00e5rd EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349\u2013357. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01973.x","journal-title":"Clin Otolaryngol"},{"key":"4980_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128083","volume":"293","author":"J Xing","year":"2025","unstructured":"Xing J et al (2025) Revisiting therapeutic options against resistant Klebsiella pneumoniae infection: phage therapy is key. Microbiol Res 293:128083. https:\/\/doi.org\/10.1016\/j.micres.2025.128083","journal-title":"Microbiol Res"},{"key":"4980_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128228","volume":"298","author":"M Yao","year":"2025","unstructured":"Yao M, Zhu Y, Duan JA, Xiao P (2025) Phage therapy: a novel approach to combat drug-resistant pathogens. Microbiol Res 298:128228. https:\/\/doi.org\/10.1016\/j.micres.2025.128228","journal-title":"Microbiol Res"},{"key":"4980_CR139","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1126\/science.aad6791","volume":"350","author":"R Young","year":"2015","unstructured":"Young R, Gill JJ (2015) Phage therapy redux-What is to be done? Science 350:1163\u20131164. https:\/\/doi.org\/10.1126\/science.aad6791","journal-title":"Science"},{"key":"4980_CR140","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.chest.2020.03.013","volume":"158","author":"EC Zabor","year":"2020","unstructured":"Zabor EC, Kaizer AM, Hobbs BP (2020) Randomized Controlled Trials. Chest 158:S79\u2013s87. https:\/\/doi.org\/10.1016\/j.chest.2020.03.013","journal-title":"Chest"},{"key":"4980_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121638","volume":"16","author":"B Zalewska-Pi\u0105tek","year":"2023","unstructured":"Zalewska-Pi\u0105tek B (2023) Phage therapy-challenges, opportunities and future prospects. Pharmaceuticals (Basel) 16:1638. https:\/\/doi.org\/10.3390\/ph16121638","journal-title":"Pharmaceuticals (Basel)"},{"key":"4980_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2025.128278","volume":"300","author":"S Zhang","year":"2025","unstructured":"Zhang S, Kim JC, Ahn J (2025) Phage engineering strategies to expand host range for controlling antibiotic-resistant pathogens. Microbiol Res 300:128278. https:\/\/doi.org\/10.1016\/j.micres.2025.128278","journal-title":"Microbiol Res"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-026-04980-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-04980-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:25:58Z","timestamp":1787909158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-026-04980-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":142,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4980"],"URL":"https:\/\/doi.org\/10.1007\/s00203-026-04980-w","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"435"}}